Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

@inproceedings{Neelapu2016KteC19C,
  title={Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1},
  author={Sattva S Neelapu and Frederick L Locke and Nancy L. Bartlett and Lazaros J. Lekakis and David B. Miklos and Caron A. Jacobson and Ira Braunschweig and Olalekan O. Oluwole and Tanya Siddiqi and Yi Lin and John M. Timmerman and Patrick J. Stiff and Jonathan W. Friedberg and Ian W Flinn and Andre Goy and Mitchell R Smith and Abhinav Deol and Umar Farooq and Peter A. Mcsweeney and Javier Mu{\~n}oz and Irit Avivi and Januario E. Castro and Jason R Westin and Julio C Chavez and Armin Ghobadi and Krishna V Komanduri and Ronald Levy and Eric D. Jacobsen and Patrick M. Reagan and Adrian Bot and John M. Rossi and Lynn Navale and Yizhou Jiang and Jeff Aycock and Meg Elias and Jeff Wiezorek and William Y. Go},
  year={2016}
}
Background: Patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL) have poor outcomes with currently available therapies, with a complete response (CR) rate of 8%, a partial response (PR) rate of 18%, and median overall survival (OS) of 6.6 months (mo) as demonstrated in the 635 pt SCHOLAR-1 meta-analysis (Crump, ASCO 2016; abstract 7516). ZUMA-1 is the first multicenter trial of anti-CD19 chimeric antigen receptor (CAR) T cells in refractory, aggressive NHL ([NCT02348216][1… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Clinical Trials of CART Cells in China

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Clinical trials of CAR-T cells in China

  • Journal of Hematology & Oncology
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Chimeric Antigen Receptor T-Cell Therapy.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2018